Álvaro H Borges1, Jemma L O'Connor2, Andrew N Phillips2, James D Neaton3, Birgit Grund4, Jacqueline Neuhaus3, Michael J Vjecha5, Alexandra Calmy6, Kersten K Koelsch7, Jens D Lundgren1. 1. Centre for Health and Infectious Diseases Research (CHIP), Department of Infectious Diseases, Rigshospitalet-University of Copenhagen, Denmark. 2. Research Department of Infection and Population Health, University College London, United Kingdom; 3. Division of Biostatistics, School of Public Health. 4. School of Statistics, University of Minnesota, Minneapolis. 5. Institute for Clinical Research Veterans Affairs Medical Center, Washington D.C. 6. HIV Unit, Division of Infectious Diseases, Geneva University Hospitals, Switzerland; 7. The Kirby Institute for Infection and Immunity in Society, University of New South Wales, and St. Vincent's Hospital, Sydney, Australia.
Abstract
BACKGROUND: Interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels are linked to adverse outcomes in human immunodeficiency virus (HIV) infection, but the strength of their associations with different clinical end points warrants investigation. METHODS: Participants receiving standard of care in 2 HIV trials with measured biomarker levels were followed to ascertain all-cause death, non-AIDS-related death, AIDS, cardiovascular disease (CVD), and non-AIDS-defining malignancies. Hazard ratios (HRs) and 95% confidence intervals (CIs) of each end point for quartiles and log2-transformed IL-6, hsCRP, and D-dimer levels were calculated using Cox models. Marginal models modelling multiple events tested for equal effects of biomarker levels on different end points. RESULTS: Among 4304 participants, there were 157 all-cause deaths, 117 non-AIDS-related deaths, 101 AIDS cases, 121 CVD cases, and 99 non-AIDS-defining malignancies. IL-6 was more strongly associated with most end points, compared with hsCRP. IL-6 appeared to be a stronger predictor than D-dimer for CVD and non-AIDS-defining malignancies, but 95% CIs overlapped. Independent associations of IL-6 were stronger for non-AIDS-related death (HR, 1.71; 95% CI, 1.43-2.04) and all-cause death (HR, 1.56; 95% CI, 1.33-1.84) and similar for CVD (HR, 1.35; 95% CI, 1.12-1.62) and non-AIDS-defining malignancies (HR, 1.30; 95% CI, 1.06-1.61). There was heterogeneity of IL-6 (P < .001) but not hsCRP (P = .15) or D-dimer (P = .20) as a predictor for different end points. CONCLUSIONS: IL-6 is a stronger predictor of fatal events than of CVD and non-AIDS-defining malignancies. Adjuvant antiinflammatory and antithrombotic therapies should be tested in HIV-infected individuals.
BACKGROUND: Interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP), and D-dimer levels are linked to adverse outcomes in human immunodeficiency virus (HIV) infection, but the strength of their associations with different clinical end points warrants investigation. METHODS:Participants receiving standard of care in 2 HIV trials with measured biomarker levels were followed to ascertain all-cause death, non-AIDS-related death, AIDS, cardiovascular disease (CVD), and non-AIDS-defining malignancies. Hazard ratios (HRs) and 95% confidence intervals (CIs) of each end point for quartiles and log2-transformed IL-6, hsCRP, and D-dimer levels were calculated using Cox models. Marginal models modelling multiple events tested for equal effects of biomarker levels on different end points. RESULTS: Among 4304 participants, there were 157 all-cause deaths, 117 non-AIDS-related deaths, 101 AIDS cases, 121 CVD cases, and 99 non-AIDS-defining malignancies. IL-6 was more strongly associated with most end points, compared with hsCRP. IL-6 appeared to be a stronger predictor than D-dimer for CVD and non-AIDS-defining malignancies, but 95% CIs overlapped. Independent associations of IL-6 were stronger for non-AIDS-related death (HR, 1.71; 95% CI, 1.43-2.04) and all-cause death (HR, 1.56; 95% CI, 1.33-1.84) and similar for CVD (HR, 1.35; 95% CI, 1.12-1.62) and non-AIDS-defining malignancies (HR, 1.30; 95% CI, 1.06-1.61). There was heterogeneity of IL-6 (P < .001) but not hsCRP (P = .15) or D-dimer (P = .20) as a predictor for different end points. CONCLUSIONS: IL-6 is a stronger predictor of fatal events than of CVD and non-AIDS-defining malignancies. Adjuvant antiinflammatory and antithrombotic therapies should be tested in HIV-infected individuals.
Authors: Claude Béténé A Dooko; Stephane De Wit; Jacqueline Neuhaus; Adrian Palfreeman; Rosalie Pepe; James S Pankow; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2014-12-15 Impact factor: 3.731
Authors: Álvaro H Borges; Jemma L O'Connor; Andrew N Phillips; Frederikke F Rönsholt; Sarah Pett; Michael J Vjecha; Martyn A French; Jens D Lundgren Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: M Cushman; R N Lemaitre; L H Kuller; B M Psaty; E M Macy; A R Sharrett; R P Tracy Journal: Arterioscler Thromb Vasc Biol Date: 1999-03 Impact factor: 8.311
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Daniel I Swerdlow; Michael V Holmes; Karoline B Kuchenbaecker; Jorgen E L Engmann; Tina Shah; Reecha Sofat; Yiran Guo; Christina Chung; Anne Peasey; Roman Pfister; Simon P Mooijaart; Helen A Ireland; Maarten Leusink; Claudia Langenberg; Ka Wah Li; Jutta Palmen; Philip Howard; Jackie A Cooper; Fotios Drenos; John Hardy; Michael A Nalls; Yun Rose Li; Gordon Lowe; Marlene Stewart; Suzette J Bielinski; Julian Peto; Nicholas J Timpson; John Gallacher; Malcolm Dunlop; Richard Houlston; Ian Tomlinson; Ioanna Tzoulaki; Jian'an Luan; Jolanda M A Boer; Nita G Forouhi; N Charlotte Onland-Moret; Yvonne T van der Schouw; Renate B Schnabel; Jaroslav A Hubacek; Ruzena Kubinova; Migle Baceviciene; Abdonas Tamosiunas; Andrzej Pajak; Roman Topor-Madry; Sofia Malyutina; Damiano Baldassarre; Bengt Sennblad; Elena Tremoli; Ulf de Faire; Luigi Ferrucci; Stefania Bandenelli; Toshiko Tanaka; James F Meschia; Andrew Singleton; Gerjan Navis; Irene Mateo Leach; Stephan J L Bakker; Ron T Gansevoort; Ian Ford; Stephen E Epstein; Mary Susan Burnett; Joe M Devaney; J Wouter Jukema; Rudi G J Westendorp; Gert Jan de Borst; Yolanda van der Graaf; Pim A de Jong; Anke-Hilse Mailand-van der Zee; Olaf H Klungel; Anthonius de Boer; Pieter A Doevendans; Jeffrey W Stephens; Charles B Eaton; Jennifer G Robinson; JoAnn E Manson; F Gerry Fowkes; Timonthy M Frayling; Jackie F Price; Peter H Whincup; Richard W Morris; Debbie A Lawlor; George Davey Smith; Yoav Ben-Shlomo; Susan Redline; Leslie A Lange; Meena Kumari; Nick J Wareham; W M Monique Verschuren; Emelia J Benjamin; John C Whittaker; Anders Hamsten; Frank Dudbridge; J A Chris Delaney; Andrew Wong; Diana Kuh; Rebecca Hardy; Berta Almoguera Castillo; John J Connolly; Pim van der Harst; Eric J Brunner; Michael G Marmot; Christina L Wassel; Steve E Humphries; Philippa J Talmud; Mika Kivimaki; Folkert W Asselbergs; Mikhail Voevoda; Martin Bobak; Hynek Pikhart; James G Wilson; Hakon Hakonarson; Alex P Reiner; Brendan J Keating; Naveed Sattar; Aroon D Hingorani; Juan Pablo Casas Journal: Lancet Date: 2012-03-14 Impact factor: 79.321
Authors: Birgit Grund; Jason V Baker; Steven G Deeks; Julian Wolfson; Deborah Wentworth; Alessandro Cozzi-Lepri; Calvin J Cohen; Andrew Phillips; Jens D Lundgren; James D Neaton Journal: PLoS One Date: 2016-05-12 Impact factor: 3.240
Authors: Anna D Nordell; Matthew McKenna; Álvaro H Borges; Daniel Duprez; Jacqueline Neuhaus; James D Neaton Journal: J Am Heart Assoc Date: 2014-05-28 Impact factor: 5.501
Authors: Liisa Hantsoo; Sara Kornfield; Claudia Iannelli; Jessica Podcasy; David Metzger; Mary D Sammel; C Neill Epperson Journal: J Behav Med Date: 2019-03-19
Authors: Ahmed Tawakol; Amorina Ishai; Danny Li; Richard A P Takx; Sophia Hur; Yannick Kaiser; Miguel Pampaloni; Adam Rupert; Denise Hsu; Irini Sereti; Rémi Fromentin; Nicolas Chomont; Peter Ganz; Steven G Deeks; Priscilla Y Hsue Journal: JAMA Cardiol Date: 2017-02-01 Impact factor: 14.676
Authors: Brian B Hart; Anna D Nordell; Jason F Okulicz; Adrian Palfreeman; Andrzej Horban; Eynat Kedem; Jacqueline Neuhaus; David R Jacobs; Daniel A Duprez; James D Neaton Journal: J Acquir Immune Defic Syndr Date: 2018-01-01 Impact factor: 3.731
Authors: Andreas Ronit; Shweta Sharma; Jason V Baker; Rosie Mngqibisa; Tristan Delory; Luis Caldeira; Nicaise Ndembi; Jens D Lundgren; Andrew N Phillips Journal: J Infect Dis Date: 2018-01-17 Impact factor: 5.226